

(19) World Intellectual Property
Organization
International Bureau



(10) International Publication Number
WO 2012/021991 A8

(43) International Publication Date
23 February 2012 (23.02.2012)

WIPO | PCT

- (51) **International Patent Classification:**
C07C 335/32 (2006.01) A61K 31/4709 (2006.01)
A61K 31/17 (2006.01) A61P 31/16 (2006.01)
- (21) **International Application Number:**
PCT/CA2011/050497
- (22) **International Filing Date:**
12 August 2011 (12.08.2011)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**
61/373,807 14 August 2010 (14.08.2010) US
- (71) **Applicants (for all designated States except US):** VERSITECH LIMITED [CN/CN]; Room 405A, Cyberport 4, 100 Cyberport Road, Hong Kong, Hong Kong (CN). BRITISH COLUMBIA CANCER AGENCY BRANCH [CA/CA]; 600 West 10th Avenue, Vancouver, British Columbia V5Z 4E6 (CA).
- (72) **Inventors; and**
- (75) **Inventors/Applicants (for US only):** JONES, Steven, J. [CA/CA]; 806-1833 Crowe Street, Vancouver, British Columbia V5Y 0A2 (CA). LAU, Allan, Sik-Yin [CA/CN]; Unit 15B, Senior Staff Quarters, Grantham Hospital, 125 Wong Chuk Hang Road, Aberdeen, Hong Kong (CN). AN, Jianghong [CA/CA]; 202-5788 Birney Avenue, Vancouver, British Columbia V6S 0A2 (CA). LAW, Hing-Yee [CN/CN]; Flat 5C, Block 7, Chi Fu Fa Yuen, Pokfulam, Hong Kong (CN). LEE, Chun-Wai, Davy [CN/CN]; Flat C, 11/F, Block 33A, South Horizons, Apleichau, Hong Kong (CN).
- (74) **Agents:** CHAKRAPANI, Mukundan et al.; Borden Ladner Gervais LLP, World Exchange Plaza, 100 Queen Street, Suite 1100, Ottawa, Ontario K1P 1J9 (CA).
- (81) **Designated States (unless otherwise indicated, for every kind of national protection available):** AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
- (84) **Designated States (unless otherwise indicated, for every kind of regional protection available):** ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
- Declarations under Rule 4.17:**
- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
 - of inventorship (Rule 4.17(iv))
- Published:**
- with international search report (Art. 21(3))
- (48) **Date of publication of this corrected version:**
28 March 2013

[Continued on next page]

(54) **Title:** ANTI-VIRAL CARBAMIMIDOTHIOIC ACID ESTERS





Figure 1A



(57) **Abstract:** Carbamimidothioic acid esters of formula (I) and 2-nitro-N-[4-(pyridin-4-ylamino)phenyl]-4-(quinolin-4-ylamino)benzamide are used for the treatment of influenza, and for the inhibition of a viral RNA-dependent RNA polymerase. Formulae (I), (II).

(15) **Information about Correction:**
see Notice of 28 March 2013